Assessing Clinical Outcomes between 18 Gy in 2 Fractions vs 21 Gy in 3 Fractions of Brachytherapy after Concurrent Chemoradiotherapy in Locally Advanced Carcinoma Cervix
Farjana Rashid *
National Institute of Cancer Research and Hospital, Mohakhali, Dhaka, Bangladesh.
Kamrun Nahar Liza
National Institute of Cancer Research and Hospital, Mohakhali, Dhaka, Bangladesh.
Zaki Ibne Bari
Department of Surgery, President Abdul Hamid Medical College and Hospital, Karimganj, Bangladesh.
*Author to whom correspondence should be addressed.
Abstract
Background: There is a multitude of problems encountered during the management of critical conditions in low-resource settings. Reducing the administration of brachytherapy from 3 to 2 fractions will assist cervical cancer patients by decreasing the treatment costs and as well as repeated attendances in the hospitals.
Objective: The research was carried out to compare the clinical outcomes following treatment of locally advanced carcinoma cervix with two fractions of high dose-rate brachytherapy following conventional concurrent chemoradiation.
Method: A quasi-experimental approach was employed. The study took place in National Institute of Cancer Research & Hospital, Dhaka, Bangladesh from July 2023 to December 2024. A sum of 66 locally advanced cervical cancer patients were divided into 2 arms; Arm A receiving 18 Gy in 2 fractions of brachytherapy and Arm B getting 21 Gy in 3 fractions of brachytherapy.
Findings: We discovered that, 51.5% vs. 48.5% were illiterate, 90.9% vs. 87.9% had early marriages; 51.5% vs. 60.6% patients had 2 or more children. Most of the patients, 54.5% vs 57.6% were in stage IIB of FIGO staging. No statistically significant association was determined between per vaginal findings after completion of treatment regimen as well as during the follow-up sessions. Besides, 66.7% vs. 72.7% had abnormal vaginal bleeding, 54.6% vs 63.6% had unusual per vaginal discharges and 75.8% vs 63.6% had pain in pelvic region before the treatment had started. However, during the follow-ups, all the complaints had reduced grossly in both the arms; for instance, during the 3rd follow-up, 1 patient in Arm B had mild bleeding; 9.1% vs 3.1% cases had unusual discharges and 3.1% vs. 6.1% mentioned pelvic pain. No statistically significant association was established between the 2 groups in this context. Lastly, 100.0% vs 94.7% stage IIB participants demonstrated complete response. Stable disease was found in 1 patient of stage IVA in Arm B.
Conclusion: Therapeutic regimens of reduced duration may offer better patient compliance and reduced burden on healthcare facilities in low-resource zones provided clinical outcomes are not compromised. The implementation of 18 Gy in 2 fraction regimen will aid in overcoming various challenges on both patient’s and hospital’s end.
Keywords: Cervical cancer, brachytherapy, concurrent chemoradiotherapy, clinical outcomes, malignancy